Navigation Links
Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium
Date:1/12/2009

MONTVALE, N.J., Jan. 12 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (NYSE Alternext US: SYI) has completed enrollment of its BENEFICIAL study, a Phase 2 double-blind, placebo-controlled, randomized trial of the Company's compound alagebrium. The study is designed to measure the effect of alagebrium on exercise tolerance in patients with chronic systolic heart failure. In addition, the Company anticipates completing enrollment of its BREAK (Beginning a Randomized Evaluation of the A.G.E. [Advanced Glycation End Product] Breaker Alagebrium in Diastolic Heart Failure) study in the First Quarter of 2009. BREAK, a randomized, double-blind, placebo controlled study, evaluates whether alagebrium (200mg twice daily) can improve exercise tolerance, as measured by the 6-minute walk test, in patients diagnosed with diastolic heart failure.

"We are extremely pleased with the progress thus far in our clinical program for alagebrium," said Noah Berkowitz, M.D., Ph.D., President and Chief Executive Officer of Synvista Therapeutics, developer of alagebrium. "Based on our dialogue with the FDA, we believe that exercise tolerance is an approvable regulatory endpoint, in patients with systolic or diastolic heart failure. Accordingly, we look forward to the timely completion of these studies which could provide proof of efficacy and a partial basis for drug approval."

About Alagebrium

Alagebrium is Synvista's clinical candidate for interfering with A.G.E.-related sclerosis and fibrosis of the heart, kidney and other tissues leading to heart failure, diabetic nephropathy and other disorders. It is a proprietary A.G.E. crosslink breaker that is designed to function unlike any previously developed pharmaceutical agents to reverse the disease states associated with age or diabetes-related stiffening of vessels, tissues and organs. Alagebrium has completed a series of
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics to Present at the BIO InvestorForum 2007
2. Synvista Therapeutics to be Featured on Wallst.net
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
7. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Synvista Therapeutics Announces Initiation of the BREAK Study of Alagebrium for Diastolic Heart Failure
9. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
10. Synvista Therapeutics Posts Letter to Stockholders on Web Site
11. Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the American Heart Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Toronto, Canada (PRWEB) January 15, 2014 ... perspectives on nonclinical and clinical safety assessment in biosimilars. ... a path for biosimilar drug development, however the complex ... regards to quality, safety and efficacy extremely challenging. Based ...
(Date:1/15/2014)... DTS Language Services, Inc . is ... for Life Science organizations who need document translations. Clients ... of their documents in advance with a selection of nearly ... translations, often a critical factor in clinical and scientific fields, ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 ... Almshouse Road, Warrington, Pa. , Details: The Hepatitis ... finding a cure for hepatitis B and improving the quality ... Crystal Ball on Friday, April 11 at Warrington Country Club ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... , , , , Multiporator / Electroporator 2510 , , , ... Transformation Protocol , Protocol No. 4308 915.538 04/2002 , ... , , , , ... , Cell type , Bacteria, gram ...
... , , , Multiporator / Electroporator 2510 , , , , , ... Transformation Protocol , , ... , , , , , , , , ... Azotobacter vinelandii, , , ...
... , , , Multiporator / Electroporator 2510 , , , , , ... Transformation Protocol , Protocol No. 4308 915.501 04/2002 , ... , , , ... , Cell type , Bacteria, gram negative, ...
Cached Biology Technology:Bifidobacterium animalis 2Azotobacter vinelandii 2Actinomyces viscosus 2
(Date:4/21/2014)... mountains across the western United States are dying, thanks to ... inner bark. , Some species of the beetles, such ... Others live in dead, weakened or dying hosts. , In ... of more than 3.4 million acres of pine trees. , ... flow and water quality? Plenty, according to new research findings ...
(Date:4/21/2014)... are on the decline in the Galpagos. , A new ... indicates numbers of the iconic birds, known for their ... attract mates, have fallen more than 50 percent in less ... is probably due to an unexplained disappearance of sardines from ... at Wake Forest University and the study,s principal investigator. This ...
(Date:4/21/2014)... from Pittsburgh University, find how lipid mediators are ... Chemistry. Lipid mediators are molecules playing an important ... some of them has earned a Nobel prize ... power plants", the organelles where oxidation of various ... a molecule universally used for storage and transportation ...
Breaking Biology News(10 mins):Earth Week: Bark beetles change Rocky Mountain stream flows, affect water quality 2Earth Week: Bark beetles change Rocky Mountain stream flows, affect water quality 3Lack of breeding threatens blue-footed boobies' survival 2Lack of breeding threatens blue-footed boobies' survival 3The anti-inflammatory factory 2The anti-inflammatory factory 3
... of the Neanderthal genome persists in modern human populations. ... 665 people from Europe and East Asia shows that more ... DNA of this contemporary group, whose genetic information is part ... that someone of non-African descent may have inherited approximately 1 ...
... thousand years ago, Homo sapiens migrating out ... diverged from modern humans hundreds of thousands of years ... Neanderthals mingled, and over time, produced children with genes ... collision between two distinct populations remain alive in the ...
... a single gene in honey bees separates the queens from ... University and Wayne State University unraveled the gene,s inner workings ... Biology Letters . The gene, which is responsible for leg ... of bees, ability to carry pollen. "This gene is ...
Cached Biology News:Neanderthal lineages excavated from modern human genomes 2Neanderthal lineages excavated from modern human genomes 3When populations collide 2When populations collide 3When populations collide 4Single gene separates queen from workers 2